ArcticZymes Technologies — M&A Activity 2017

Aug 25, 2017

Biotec has entered into a supply agreement for M-Gard® in the USA

(Tromsø, 25 August 2017) Biotec Pharmacon ASA's ("Biotec", OSE: BIOTEC) subsidiary Biotec BetaGlucans has today signed a Term Sheet to supply M-Gard® to a US customer for consumer health applications

Biotec BetaGlucans AS has signed a Term Sheet agreement to enter into a business relationship with a US-company, for deliveries of its M-Gard®-ingredient for use in their consumer health products. Deliveries will start immediately while the parties work on the complementary Supply Agreement. According to the Term Sheet signed, the customer will receive certain rights based on a minimum purchase volume of NOK 12 mill over the 3 years initial term.

"We have been exploring the possibility to re-enter the consumer health market with our beta-glucan ingredient M-Gard® over the last months and have received positive feedback from several potential customers. This Term Sheet represent the first agreement where Biotec BetaGlucans provides bulk ingredient intended for end-user products sold in the US market. It will also provide an important reference to re-establish ourselves as a long-term supplier to this industry," says Biotec Pharmacon's CEO Svein W. F. Lien.

For more information, please contact: CEO Svein W. F. Lien, tel +47 922 89 323

About Biotec BetaGlucans AS:

Biotec BetaGlucans is a wholly owned subsidiary of Biotec Pharmacon ASA. Biotec BetaGlucans develops and manufactures novel immunomodulating products for business areas including Woulgan®, a premium priced product in the advanced wound care market, animal feed, consumer health, cosmetics, medical devices and pharmaceuticals. M-Gard® particulate is Biotec BetaGlucans' flagship product for immune-related consumer health applications. For more information please visit our company website at https://biotec.no/ or our M-Gard®-product website at https://m-gard.com/.

About Biotec Pharmacon ASA:

Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.